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ABSTRACT

Unassisted, the lifetime of many proteins outside their natural environment is very
short. Scientists generally need to extract the sample, often in remote locations, and then
transport, isolate, and store such biospecimens relatively far from the point of origin in
order to study them. Currently, the most commonly used methods for storage of
biospecimens are cryopreservation or refrigeration which, though effective, have their
fair share of flaws. Cryopreservation and refrigeration-based storage of biospecimens
requires a great deal of space and other resources to be effective. Furthermore, the
hardware required for cold storage does not transport well. These factors make such
storage methods impractical for use in the field and even some laboratories[1-3]. Due to
repeated strain on biomolecules from crystallization, rapid degradation occurs after
repeated freezing and thawing; this problem could be avoided by storing specimens at
ambient temperatures. Herein, we report a novel method for long-term room-temperature
aqueous biomolecule storage utilizing rapidly fabricated silica sol-gel networks. By
adjusting solution conditions such as acidity, salinity, buffer concentration, and silica
density, it is possible to tailor sol-gel chemistry to create hospitable silica structures to
support a variety of biomolecules. We have demonstrated the preservation of RNA and
Hemoglobin samples for up to 28 days and 31 days respectively, under ambient
iv

conditions, using this technique. Upon coupling the amenability of the sol-gel structure
with a contemporary rapid synthesis method, silica sol-gels become Capture and Release
Gels for Optimized Storage (CaRGOS).
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I. INTRODUCTION

Biomolecules are difficult to store but important for human health studies and
molecular biology research. Their complex chemistry lends itself to aid in finely tuned
processes, however when taken out of their natural environment the same complex
chemistry makes them unstable.
The proneness to degradation of these materials make it very difficult to preserve
samples between studies and establish standard operating procedures between
institutions. For example, two institutions working on the exact same material may get
different results owing to the varying states of degradation between the two samples
caused by differences in transportation, handling, etc. These issues lead to inconsistencies
between studies conducted at separate facilities and could cast doubt on independentlyreported conclusions [4]. In order to further standardize the study of biospecimens, efforts
must be made to combat their natural fragility. To this end, efforts have been made to
stabilize biospecimens for transport and study.
Cryopreservation under liquid nitrogen is a well-established method for indefinite
storage of unstable biomolecules, but it requires a great deal of infrastructure, safeguards,
and maintenance[5]. While there are commercial biobanks which can indefinitely store
large numbers of individual samples cryogenically and distribute them when needed, this
process becomes expensive, time-consuming, and logistically difficult for less wellequipped facilities. Additionally, to study the samples, they must be removed from cold
storage and thawed [4, 6]. Johnny C. Akers et al observed that repeatedly thawing and
freezing samples for study and storage decreases the integrity incrementally with each
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cycle, making the prospect of using cold storage to extensively research one specimen
risky [4, 7].
Room temperature preservation of biomolecules has been sought after in order to
cut down on the resources required for cryopreservation. Commercial products exist to
store biomolecules at room temperature, but these products generally utilize ultra-dry
conditions [6, 8]. Accessing and storing samples with these products requires multiple
rehydration and dehydration steps which incrementally degrade the sample [5].
Based on the strengths and flaws of cryopreservation, ultra-dry storage, and
traditional sol-gels, an ideal technique for encapsulation and preservation of biomolecules
should be:


Done in an aqueous medium which is as inert as possible



Repeatable in any given location



Easy enough to carry out with basic instruction



Sterile [9-11]

The biomolecule should be prepared for long-term storage at ambient temperatures,
protected from protease and nuclease, and be easily recoverable (34). Current
technologies are unable to fulfill all these requirements.
Providing all institutions, individuals, and facilities in need of long-term robust
storage of various biomolecules a means to do so quickly, easily, and at ambient
conditions can be achieved through Capture and Release Gels for Optimized Storage
(CaRGOS). With very little manufacturing time and cost, CaRGOS sol-gel technology
preserves biomolecules and biospecimens for storage and transport at ambient to aboveambient temperatures. Sample storage and recovery is possible for anyone with access to

2

the requisite reagent chemicals and a microwave. The technique provides continuous
access to the sample without time-consuming and damaging thawing or rehydration steps.
CaRGOS would facilitate processing of biospecimens collected in remote areas by
enabling transportation to analytical facilities without specialized accommodations such
as cryopreservation equipment. The adoption of CaRGOS will not only circumvent the
resource consumption required to consistently operate cold storage devices but will also
improve the integrity of the biomolecules during experiments at ambient temperatures.
The following text shall present a new and novel method of biomolecule
preservation which not only satisfies the necessary criteria to be useful but also goes
above and beyond previous technologies. Through careful modification of solution
chemistry and use of a standard microwave oven, silica sol-gel becomes the powerful
Capture and Release Gel for Optimized Storage (CaRGOS). In order to characterize the
performance of CaRGOS, microRNA 21 and Hemoglobin have been encapsulated in
CaRGOS for extended periods, and their integrity assessed at several time intervals
before successful recovery of the specimens.

3

SOL – GEL CHEMISTRY

4

OVERVIEW

Sol-gel techniques have been looked towards as a possible solution for biomolecule
storage since the 1930s [12]. Due to their optical clarity and porous nature, immobilizing
a protein within a sol-gel network allows for study and application of the molecule’s
native structure and function without exposure to potentially harmful conditions [13, 14].
Sol-gels are colloidal suspensions that exist as a collection of particles that agglomerate
or form complex branching network that ultimately forms the gel [12]. Through the solgel method, researchers have been able to explore unique formulations of biocompatible
ceramics to function as support materials, implants, drug delivery, and stimulants for
certain biological cell responses[14, 15]. The physical characteristics of the sol-gel such
as particle size, network geometry, porosity, and surface potential can be altered during
or post-synthesis with relative ease to assist in the study of biomaterials[16].
The use of silica sol-gels has received special attention, as it is a relatively simple
aqueous process with tunable salinity and thus is inherently biocompatible [17, 18].
Though silica sol-gels show great promise, the most common preparation methods do not
lend themselves well toward widespread adoption. Traditionally, silica sol-gels
implement alcohols as co-solvents, contain acidic or basic catalysts, or utilize complex
formulations which do not scale well. The co-solvents and catalysts are potentially
harmful to biospecimens if they are present in the final gel [19-26].
By employing microwave hydrolysis, biocompatible sol-gels can be synthesized at a
faster rate than ever before without employing co-solvents or acidic/basic catalysts.
Relatively low TMOS precursor concentration formulations have been fully hydrolyzed
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within 30 seconds of microwave exposure and the resulting sol-gels have shown promise
as biomaterial storage materials.
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II. INSTRUMENTATION AND EQUIPMENT

A. Infrastructure and Equipment
Fume hood
Microwave 1200 Watt with viewing window in order to monitor samples during use.
Vortex machine
Dynamic Light Scattering (DLS) machine
Fourier Transform Infrared spectrophotometer
UV-Vis spectrophotometer
Reva Educational Raman platform.
Micropipettes capable of measuring as little as 0.5 uL
Sealable glass vessel with 2-3 ventilation holes in the cap for gasified methanol
B. Chemicals
Tetramethyl orthosilicate 99% (TMOS) from Acros Organics.
Tris-EDTA (TE) buffer from Sigma Aldrich.
Sodium Chloride (NaCl) from Sigma Aldrich.
Polymethylmethacrylate UV-grade cuvettes from VWR.

7

III. Procedure

A. TMOS Microwave Hydrolysis.
To prepare the sol-gel, TMOS and NFW were combined in the desired v/v %
concentration in a clear glass vial capped with a modified top to vent. The mixture was
agitated with a Vortex mixer to uniformly disperse the components. The vented container
was placed in a 1200-watt microwave and microwaved at full power for 15-30 seconds or
until boiling. If the mixture began boiling prematurely, it was removed, mixed, and
allowed to settle for a few seconds before completing the microwave process. The
microwaves served to hydrolyze TMOS, forming silicic acid and methanol. Both
products of this reaction are miscible in water, so if any distinct TMOS bubbles were still
observed within the mixture, the process was repeated until an optically clear
homogenous liquid was achieved. The mixture was allowed to sit uncovered in a fume
hood and off-gas the bulk of the gaseous methanol before proceeding.
B. UV-Vis Spectroscopy
The utility of sol-gels as a storage medium while also allowing spectral analysis
without total removal of the sample was explored. UV-vis spectroscopy was performed
on a set of four sol-gels of concentrations 0.5, 1.0, 5.0, and 10.0% v/v after hydrolysis
and at periods of 1, 4, 7, 10, and 14 days under ambient room conditions. An Agilent
Cary win 60 UV-Vis, at a range of 280 – 1000 nm, collecting data every 1 nm, with an
average time of 0.1 second, and a scan rate of 600 nm/minute. The resulting spectra
illustrate the ability of a sol-gel network to allow for reliable and accurate analysis of
stored materials at different network densities as they continue to form.
8

C. Raman Spectroscopy
Raman spectra was collected for TMOS/H2O before and after microwave hydrolysis
as well as CaRGOS samples using a Reva Educational Raman platform. The laser power
of 450.0 mW and current 959.0 mA was optimized to analyze vibrational and rotational
motions of silica (Si-O) bonds. The laser temperatures [diode = 30 °C; Case = 24.4 °C]
and spectrometer temperature [ 23.1 °C] were optimized for collecting Raman spectra.
D. Fourier Transform Infrared Spectroscopy (FTIR)
FTIR was performed using a PerkinElmer Spectrum 100 FT-IR Spectrophotometer.
Each measurement was taken between 550 and 2500 cm -1, 8 scans per measurement, and
corrected using baseline and attenuated total reflection correction.
E. Dynamic Light Scattering (DLS)
A NanoBrook Zeta PALS from Brookhaven Instruments was used to collect DLS
and zeta potential measurements. Three scans consisting of 20 cycles were performed and
averaged were used to form the results presented.
F. Zeta Potential Measurements
Using the NanoBrook Zeta PALS from Brookhaven Instruments, zeta potential
measurements were collected using 80 Hz frequency. Two continuous measurements
totaling in 4 minute collection time were used to form the results of each dataset
presented.

9

IV. Results and Discussion of Results

A. Optics.
Silica sol-gels have been explored as biomolecule storage methods in the past due to
their optical clarity and biocompatibility [9, 27-29]. In order to assess the possibility of
sample analysis while in CaRGOS over extended periods, the optical clarity of gels was
assessed via UV-vis analysis at several points in time with 0.5, 1.0, 5.0, and 10.0 % v/v.
At times of 1, 4, and 7 days after hydrolysis as well as immediately after hydrolysis three
spectra were collected between 280 – 1000 nm and averaged for each formulation, Figure
1.

A

B

C

D

FIGURE 1 – UV-Vis Spectra of TMOS Formulations at 0 Days (A) 1 Day (B) 4 Days
(C) and 1 Week (D)
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In the lower, more aqueous concentrations (0.5 & 1.0 % v/v), there is little to no
change in the bulk of the spectra, and an > 0.1 change in absorbance at lower
wavelengths after one week. At 5 % v/v TMOS concentration, no significant change in
the spectra was observed initially before any gelation was observed, but over the course
of one day after gel formation the absorbance rose significantly. 10 % v/v TMOS formed
a gel within minutes of hydrolysis and resulted in fairly significant increase in absorbance
at lower wavelengths (280 – 600 nm). After one day, each formulation gradually
increases in absorbance at a decreasing rate. This trend, along with the absence of any
particular peaks suggests that the absorbance is increasing due to light scattering by a
more ordered silica network and suspended nanoparticles [30]. Network formation in
silica sol-gels continues until the gel is completely dried of water, so it is reasonable why
a more aqueous formulation results in higher optical stability over longer periods of time
[31-33]. Though an overall increase in absorbance was observed in solid gel samples, no
specific peaks formed across the spectra, so characterization of samples within the gel
matrix over time is still possible to some extent.
B. Hydrolysis Efficiency
The hydrolysis of TMOS precursor molecules occurs in four steps:

(Equation 1)

𝑆𝑖(𝑂𝐶𝐻 ) + 𝐻 𝑂 ↔ 𝑆𝑖(𝑂𝐶𝐻 ) (𝑂𝐻) + 𝐶𝐻 𝑂𝐻

(Equation 2) 𝑆𝑖(𝑂𝐶𝐻 ) (𝑂𝐻) + 𝐻 𝑂 ↔ 𝑆𝑖(𝑂𝐶𝐻 ) (𝑂𝐻) + 𝐶𝐻 𝑂𝐻
(Equation 3) 𝑆𝑖(𝑂𝐶𝐻 ) (𝑂𝐻) + 𝐻 𝑂 ↔ 𝑆𝑖(𝑂𝐶𝐻 ) (𝑂𝐻) + 𝐶𝐻 𝑂𝐻
(Equation 4)

𝑆𝑖(𝑂𝐶𝐻 )(𝑂𝐻) + 𝐻 𝑂 ↔ 𝑆𝑖(𝑂𝐻) + 𝐶𝐻 𝑂𝐻
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Due to the immiscible nature of TMOS and water, contact between these two
reagents can be a limiting factor. Traditionally, organic co-solvents such as alcohols are
used to homogenize the mixture in order to increase reagent interaction [33, 34]. While
this is ultimately beneficial to the hydrolysis rate, the presence of excess alcohols in
CaRGOS is detrimental to its application in long term, stable biomolecule storage.
Because the hydrolysis of TMOS inherently produces substantial amounts of methanol it
is reasonable to assume that rapid hydrolysis of an immiscible mixture would provide
enough methanol to assist in the dissolution and hydrolysis of the initial precursor, while
also minimizing alcohol concentration in the final product.
To the end of achieving a more rapid hydrolysis of precursor molecules acids and
bases are generally used as catalysts. Acidic catalysis adds a protonation fast step that
makes TMOS more susceptible to backside attack by water, while nucleophilic hydroxyl
groups readily attack the silicon atoms in alkaline catalysis [35]. Though effective,
extreme acidic and basic conditions can result in denaturation or degradation of
biological molecules making the use of such catalysts difficult for sol-gel use in
biomolecule storage without further processing, undermining the convenience of rapid
hydrolysis.
Using the techniques stated above, research has been done on sol-gel synthesis
under a variety of conditions in order to optimize hydrolysis and condensation in order to
achieve a wide range of structures with an even wider range of properties, but in most
cases great amounts of heat and time are still required.
In order to rapidly hydrolyze TMOS without the use of organic co-solvents or
acidic/alkaline catalysis, a standard microwave can instead be used. By agitating the

12

TMOS/Water mixture and quickly subjecting it to 30 seconds of microwave exposure a
homogenous mixture is rapidly achieved, Figure 2.

FIGURE 2 – TMOS Microwave Hydrolysis
Agitation by vortexing the mixture serves to disperse TMOS precursor throughout
the water in small droplets in order to maximize the contact of reagents without use of cosolvents. If left unreacted for too long the dispersed TMOS will once again aggregate and
reduce total surface contact.
Condensation of silica networks can occur in two ways, the hydroxyl group of one
precursor replaces another hydroxyl group creating an SiO2 bond and H2O, or by
replacing an alkoxy group from a not yet fully hydrolyzed precursor molecule creating an
SiO2 bond and CH3OH as seen in Equations 5 & 6.
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Water Condensation
(Equation 5)

≡ 𝑆𝑖𝑂𝐻+ ≡ 𝑆𝑖𝑂𝐻 ↔ ≡ 𝑆𝑖 − 𝑂 − 𝑆𝑖 ≡ +𝑂𝐻
Methanol Condensation

(Equation 6)

≡ 𝑆𝑖𝑂𝐻+≡ 𝑆𝑖𝑂𝐶𝐻 ↔ ≡ 𝑆𝑖 − 𝑂 − 𝑆𝑖 ≡ +𝐶𝐻 𝑂𝐻

Stoichiometrically, there should be 4X higher methanol produced during hydrolysis
of TMOS than the initial TMOS concentration. Due to the nature of this hydrolysis
method, the solution will be subjected to high temperatures and evaporation of the bulk
of methanol produced is inevitable, but a more complete hydrolysis of TMOS at any
concentration would still ultimately result in higher ratio of methanol produced to initial
precursor used.
To quantify the effectiveness of the microwave hydrolysis of TMOS at different
precursor concentrations, mixtures of varying TMOS content (0.5, 1, 5, 10 % v/v) were
hydrolyzed in a microwave for 30 seconds and the methanol content soon after hydrolysis
was measured using raman spectroscopy and a calibration curve of methanol peak
intensity at the 1033 cm-1 characteristic peak [36] (Figure 17 in APPENDIX I). Figure 3
shows the resulting spectra before and after hydrolysis of each TMOS content.
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FIGURE 3 – Raman Spectra of 0.5 – 10 % v/v TMOS Formulations
The calculated methanol concentrations after 30 second microwave hydrolysis are
displayed in TABLE I below.
TABLE I
METHANOL CONTENT OF HYDROLYZED TMOS FORMULATIONS
Sample

Methanol Peak
(Counts)
0.5 % v/v TMOS 191.0
1.0 % v/v TMOS 235.3
5.0 % v/v TMOS 1288.2
10 % v/v TMOS 2640.4

15

Methanol Content
(% v/v)
0.7356
0.9104
5.0645
10.3995

Theoretically, the molar methanol concentration should be four times that of initial
TMOS precursor. The calculated theoretical methanol concentration of fully hydrolyzed
10 mL samples is in TABLE II below.
TABLE II
THEORETICAL AND CALCULATED MOLAR METHANOL YIELD
v/v % TMOS
0.5
1.0
5.0
10.0
Theoretical Methanol
0.1353
0.2707
1.3533
2.7066
(mol/L)
Calculated Methanol
0.1331*
0.2250
1.2519
2.5707
(mol/L)
Hydrolysis Efficiency
98.4
83.1
92.5
95.0
(%)
* Value calculated from curve exceeded theoretical. Regression from other
calculated values was used

The results obtained indicate near total hydrolysis of all TMOS precursor after only 30
seconds of exposure to microwaves assuming no methanol evaporated before or during
the measurements.

C. Condensation.
1. FTIR Analysis.
With the hydrolysis of TMOS precursor characterized, it is imperative to the
application of sol-gels for biomolecule storage that condensation of the sol occurs in
order to form a silica structure. It is clear in the higher precursor formulations (5, 10 %
v/v) that silica networks were forming because they produced solid gels within 24 hours
of hydrolysis, but in the lower concentrations (0.5, 1 % v/v) no visible networks were
formed within the sol and remained aqueous. Infrared spectroscopy has been extensively
16

utilized to explore the structural characteristics of bioactive silicas fabricated through the
sol-gel method [37-39]. FTIR was utilized to confirm the formation of silica structures in
all four formulations of CaRGOS after 1 day of settling, Figure 4.

Si – OH

Si – O – Si Linear

Si – O – Si Cyclic

FIGURE 4 – FTIR of Sol-gel Solutions 1 Day After Hydrolysis
The characteristic region used to identify Si – O – Si vibrational mode is between 1000 –
1300 cm-1 [33, 37, 40, 41]. This region can be further separated into cyclic ( ~ 1080 cm 1

) and linear ( ~1030 cm-1) regions to denote the structure of the bonds [42]. Though it is

very slight, linear Si – O – Si peak is present in the aqueous formulations though it lacks
a cyclic peak implying the existence of predominantly linear sol-gel structures formed
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within. Furthermore, in the 5 and 10 % v/v TMOS gel, the presence and intensity of
cyclic peaks agrees with the observed condensation of denser gels.
2. Nanoparticle Suspension Analysis
Condensation of precursor molecules into solid particles occurs at different rates and
with different resulting structures depending on temperature, pressure, pH, and any
catalysts used. For the purpose of creating an easily prepared room temperature
biomolecule storage technique, only pH and catalyst parameters were explored.
To measure the effects of pH and catalysis on hydrolysis of precursor and
subsequent network formation, dynamic light scattering (DLS), pH, and zeta potential
measurements were taken on 0.5 % v/v TMOS samples that were hydrolyzed with and
without buffer (Tris 33 mM, EDTA 3.3 mM), salt (NaCl 50 mM), and a combination of
the two. With 24 hours of settling time after hydrolysis measurements were taken on the
dispersion of silica nanoparticles and the resulting data can be seen in TABLE III below.
TABLE III
NANOPARTICLE SUSPENSION SOLUTION PROPERTIES
Sample

DLS (nm)
35.7 ± 1.6
73.1 ± 0.3

Polydispersity Index Zeta Potential
(PDI)
(mV)
0.383 ± 0.001
-23.45 ± 1.92
0.118 ± 0.007
-4.65 ± 5.41

0.5 % v/v TMOS
0.5 % v/v TMOS,
NaCl
0.5 % v/v TMOS,
TE buffer
0.5 % v/v TMOS,
TE buffer, NaCl

pH
6.00
5.61

92.2 ± 3.5

0.331 ± 0.032

-30.10 ± 1.91

7.28

120.4 ± 0.3

0.186 ± 0.02

-13.24 ± 1.17

7.15

The data shows a clear trend in nanoparticle formation at these CaRGOS
formulations indicating the role these additives are playing in each system. Using the 0.5
% v/v TMOS formulation as a baseline for particle formation and zeta potential, the use
18

of NaCl as catalyst results in roughly double particle size while also reducing the PDI of
the suspension. TE buffer aids in particle growth more substantially than NaCl, nearly
tripling in size but offering no significant change in the PDI from a formulation without
additives. The combination of both TE buffer and NaCl results in nanoparticles that
exceed both additives alone, about four times the baseline sample with half the PDI. The
results that can be gleaned from particle size analysis are that both additives aid in
formation of larger nanoparticles, buffer has a greater effect on particle formation of
more varying sizes, while salt has a lesser effect but creates a more uniform distribution.
The reasoning behind these results can be attributed to the effects salt and buffer have on
the polymerization mechanism for nanoparticle formation. Both salt content and pH
levels affect the polymerization of silica sol-gels. Inductive and steric factors affect both
the hydrolysis and condensation reactions heavily, therefore the salinity and pH of a solgel solution will play large rolls in the resulting particles [33].
The formation of silica nanoparticles follows the Stöber method, where controlling
the pH ultimately allows synthesis of nanoparticles of controllable and uniform size. As
previously mentioned, acidic conditions can catalyze hydrolysis reactions by increasing
Si atom susceptibility to backside attack by water or hydroxyl groups expediting
hydrolysis. However, because silanol has an isoelectric pH in the more acidic regime, the
condensation reaction is more reversible resulting in smaller, less branched nanoparticles.
In the more alkaline regime (pH 7 – 10) the deprotonation of silanol hydroxyl groups
creates a far more competitive environment for nanoparticle formation through Ostwald
ripening where the larger nanoparticles dominate precursor consumption while smaller
nanoparticles that manage to form dissolve and feed larger particles [31]. It is seen in the
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collected data that the PDI of sol-gel dispersions of 0.5 % v/v TMOS precursor with pH
modification alone are sizable in comparison to the formulations with NaCl added,
regardless of pH. The addition of salt increases the rate of the Ostwald ripening of the
larger primary particles, allowing for the development of ultimately uniform
nanoparticles in shorter times, explaining the smaller PDI in both cases where NaCl is
present.
Zeta potential of a colloidal suspension is indicative of a collection of suspended
particles to aggregate and collect within a solution and is imperative to the stability of a

biomolecule adsorbed to a nanoparticle’s framework . There are well accepted regimes of
zeta potential that indicate the stability and tendency towards aggregation in solution [43-46];
poor stability (0 – 10 mV), fair stability (10 – 20 mV), good stability (20 – 30 mV) and

excellent stability (> 30 mV). To reduce the interaction with negatively charged
biomolecules, a more negative zeta potential is preferable. The results show that salt drastically
reduces stability while TE buffer adds stability. The use of both additives together brings the
solution stability to a fair level, overall reduced from both the basic formulation and the buffered
formulation, but acceptable for trials to store biomolecule samples.
3. Two-Step Rapid Nanoparticle Growth

With the effects of salt and buffer explored during hydrolysis and ultimate
nanoparticle formation, a more rapid and efficient recipe could be created. The pH
conditions induce limiting factors to the system. The use of the Stöber method to
hydrolyze TMOS at acidic pH and then introduce buffer and salt afterwards to catalyze
condensation was explored. To see the effects of buffer and salt addition after hydrolysis,
a 1.25 % v/v TMOS solution was hydrolyzed without salt or buffer and DLS
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measurements were taken immediately after hydrolysis and after addition of salt and
buffer, bringing the final silica precursor concentration to 0.5 % v/v TABLE IV.
TABLE IV
SOLUTION PROPERTIES OF SOL-GEL BEFORE AND AFTER ADDITIVES.
Sample
DLS (nm)
PDI
TMOS w/out TE Buffer *0.79 ± 0.11
0.983 ± 0.026
(1.25 % v/v)
TMOS with TE Buffer
67.22 ± 1.65
0.248 ± 0.006
and Salt (0.5 % v/v)
* Hydrodynamic size <1 nm is insignificant

Zeta Potential (mV)
-22.07 ± 1.01
-10.50 ± 1.66

The addition of catalyst and buffer after hydrolysis of TMOS shows significant
particle growth immediately. Compared to the results from hydrolysis with and without
catalyst and buffer, the two-step formulation shows much more efficient particle
formation in a shorter period. As stated previously, it has been speculated that at
protonated silane and TMOS molecules have less affinity for network formation and
aggregation than deprotonated counterparts while the reverse is true for hydrolysis [31].
The observed increase after addition of buffer and resulting rise in pH from 4.66 to 7.07
supports this claim. The pH swing is convenient because silica precursor naturally has a
pH of 4.66 after initiating hydrolysis, making it a more ideal environment for fast and
complete hydrolysis of TMOS precursor. After hydrolysis, no significant particle
formation was observed through DLS measurements and a stable zeta potential was
observed suggesting unfavorable conditions for nanoparticle formation. Once buffer and
salt are added the pH becomes more neutral at 7.07 and a hydrodynamic size of 67.22 nm
is detected with a good PDI and fair zeta potential. This spike suggests an immediate
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formation of substantial nanoparticles that have quickly reached later stages of Ostwald
ripening as depicted in Figure 5.

FIGURE 5 – Ostwald Ripening of Silane Precursor

D. Long-Term Stability
This new method of hydrolyzing TMOS was explored using Raman spectral
analysis at different steps of the process. Figure 6 shows the Raman spectra observed for
1.25 % v/v TMOS after dispersion and before microwaving (orange trace), after 15 and
30 seconds of microwaving (green or red trace respectively), after degassing methanol for
5 minutes (dark blue trace), CaRGOS solution immediately after adding buffer (upper
light blue trace), and CaRGOS solution after two weeks under ambient conditions (lower
light blue trace).
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FIGURE 6 – Raman Analysis of CaRGOS Composition Over Time
The presences of various components are signified by peaks at the following Raman
shifts:


TMOS precursor: 640-650 cm-1[31]



Silicic acid and/or sol-gel dimer: 750-780 cm-1[31]



Methanol: ~1033 cm-1[31]

Going from the top curve representing the unhydrolyzed mixture to 15 and 30
seconds of microwaving, the TMOS peak rapidly disappears signifying full hydration.
Additionally, as the TMOS peak shrinks, the representative peak for silicic acid and solgel dimers grows after microwaving. Upon addition of TE buffer, the sol-gel
concentration becomes very dilute and disappears almost entirely from the spectrum. The
growth and consistency of the methanol peak indicates the presence of the species in
CaRGOS solution even after off-gassing and dilution.
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V. Conclusions
By employing microwaves to induce TMOS hydrolysis, it has been shown that it is
possible to synthesize biocompatible silica gels and nanoparticles. Within 30 seconds of
exposure to microwaves from a common microwave unit, up to 10 % v/v TMOS
formulations have been hydrolyzed with near 100% efficiency. FTIR measurements on
the hydrolyzed solutions shows successful formation of ordered structures within sol-gels
prepared in this method at concentrations between 0.5 – 10 % v/v TMOS. Using Raman
analysis of Methanol concentration immediately after hydrolysis of TMOS precursor, it
has been shown that even in the case of 0 % methanol evaporation, a majority of alkoxy
ligand separation has been achieved.
While hydrolysis was shown to be nearly complete at up to 10% v/v TMOS
precursor concentration with microwaves alone, the condensation of resulting silanol
molecules has been further improved with solution parameters. With modification of pH
and saline concentration, the Ostwald ripening process of primary nanoparticles has been
seen to progress after only 24 hours. Nanoparticle sizes of up to ~ 120 nm were achieved
when hydrolysis and condensation were performed in 50 mM NaCl and 33 mM TE buffer
(pH 7.4).
Further experimentation was done to explore the hydrolysis and condensation
mechanism if he two were carried out under two separate steps. Under naturally acidic
conditions, the hydrolysis of 1.25 % v/v TMOS occurred rapidly and upon dilution with
TE buffer and NaCl ~ 69 nm nanoparticles were observed immediately. With fair zeta
potential of -10.5, this solution would be ready to add a biomolecule after less than 15
minutes of total synthesis time. Additionally, raman measurements of 0.5 % v/v sol-gel
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CaRGOS over 2 weeks shows solution stability over extended periods of time, suggesting
that this formulation could be used for long term storage. In conjunction with the optical
clarity observed in CaRGOS at various sol-gel concentrations over extended time, it is
entirely possible to move forward to testing with real biomolecules over extended time
while non-invasively assessing their integrity.
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OVERVIEW
This section will recount the investigation of room-temperature integrity
preservation of miRNA 21, which is a potential biomarker of tissue toxicity, cancer
diagnosis, regulator of cancer immunotherapy biomarkers [6, 8] and down-regulator of
multi-drug resistance (MDR) transporters[47, 48]. The sterile CaRGOS are achieved
utilizing a deliberately low concentration of TMOS/water suspension that is hydrolyzed
in a standard microwave. Biospecimen of interest can be added to the hydrolyzed silica
at room temperature, resulting in its stabilization. In this study, the room temperature
integrity, preservation, cancer immunotherapy and multi-drug resistance (MDR)
regulation challenges using a representative highly sensitive bioanalyte miRNA 21 have
been addressed. Specifically, a single-step ~ 100 % recovery of miRNA 21 at room
temperature using aqueous formulations of CaRGOS with extremely low silica
concentrations (0.5%) has been demonstrated. The aqueous formulations of the CaRGOS
with biospecimen are significantly versatile for downstream processing than conventional
sol-gel matrices with immobilized biomolecular entities that require physical forces to
overcome the non-covalent interactions, with a strong likelihood of rupturing biological
activity before downstream usage[49-51]. Moreover, the technique is completely
compatible with a host of proteins as well as other nucleotides such as DNA.
Although stabilization of biomolecular entities emanates from their restricted
rotation or immobilization within the silica matrices, yet the highly aqueous formulations
lacks the concentration-range requisite for such immobilization. Therefore, to validate the
mode of stabilization of biospecimen in highly aqueous formulations of CaRGOS
matrices, the inherently dual nature of silica precursors: immobilization and nuclease27

inhibition, have been investigated. In highly-stable CaRGOS formulations, a remarkable
resistance to nuclease (i.e., RNase A) was observed by demonstrating ~0 % quenching of
Ethidium bromide, thereby protecting ~100% integrity of yeast RNA. Also in this
section, it is shown that a ~ 69 nm hydrodynamic- sized aqueous formulation of CaRGOS
efficiently preserves miRNA 21 up to 28 days at above-freezing temperatures (4, 25, 40)
C with ~100% single-step recovery. The aliquots from CaRGOS sol-gel/miRNA 21
solutions have demonstrated fluorescence quenching of chemotherapeutic drug
doxorubicin supporting a realizable immunoadjuvant potential of silica matrices and
MDR circumvention by miRNA mimics[6, 8, 52, 53].
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II. Instrumentation and Equipment

A. Infrastructure and Equipment
Sterile laminar hood
Fume hood
Microwave 1200 Watt with viewing window in order to monitor samples during use.
Vortex machine
Dynamic Light Scattering (DLS) machine
Thermocycler for reverse transcriptase of miRNA (TaqMan MicroRNA Reverse
Transcription Kit)
Quantitative polymerase chain reaction (qPCR) machine
Reva Educational Raman platform.
Micropipettes capable of measuring as little as 0.5 uL
Sealable glass vessel with 2-3 ventilation holes in the cap for gasified methanol
B. Chemicals
Tetramethyl orthosilicate 99% (TMOS) from Acros Organics.
Ethidium bromide from Sigma Alderich.
Nuclease free water (NFW)
Tris-EDTA (TE) buffer from Sigma Aldrich.
Sodium Chloride (NaCl) from Sigma Aldrich.
miRNA 21 from IDT.
Yeast RNA from IDT.
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III. PROCEDURE

A. Sample Preparation

1. Buffer
Sol-gels alone do not inherently provide an accommodating environment for
biomolecules. In order to finely tune the mixtures to be more habitable for the samples,
buffers are added to control pH and add stability within silica networks.
For ideal miRNA storage, a buffer is necessary to create a habitable environment.
The buffer consisted of saline solution with varied concentrations of NaCl between 75
and 250 mM, 5.0 mM Tris-HCl (pH 7.5) and 0.5 mM EDTA which was prepared by
bringing the salt concentration of a store-bought Tris-EDTA (TE) buffer to the
appropriate level and then diluting by half.
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2.CaRGOS Solution
CaRGOS solution is prepared by combining a pure hydrolyzed TMOS solution of
the desired % v/v, a buffer solution, and the sample to be stored. Once both sol-gel and
buffer are prepared, they are combined in a 1:2 ratio for a final concentration of one third
initial sol-gel, 50 to 166 mM NaCl, 3.3 mM Tris-HCl, and 0.33 mM EDTA. RNA
specimen is thawed from cryogenic storage and added to CaRGOS for an analyte
concentration of 500 nM. Figure 7 below depicts a schematic of the CaRGOS synthesis
procedure.

FIGURE 7 – Biomolecule CaRGOS Preparation Process
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3. Reverse Transcription Recipe
A master mix was prepared before reverse transcription (RT) of the analyte was
performed using TaqMan MicroRNA Reverse Transcription Kit components. The master
mix recipe is presented in Table V.
TABLE V
MASTER MIXTURE RECIPE PER WELL FOR RT OF MIRNA 21
Component

Volume (𝝁L) per well

100 mM dNTPs

0.15

MultiScribe Reverse Transcriptase, 50
U/𝜇L

1.00

10X Reverse Transcription Buffer

1.50

RNase Inhibitor 20 U/𝜇L

0.19

Nuclease-free water

4.16

5X miRNA Primer

3.00

Total volume (𝜇L)

10.00

RT components and 5X miRNA Primer were thawed from freezing and vortexed
before combining. Once the master mix was prepared, 10 μL was pipetted into one well
in a 200μL 96-well reaction plate for each desired reaction. 5 μL of each miRNA sample
to be analyzed was pipetted into a well with master mix which was subsequently capped
and mixed gently in order to settle the solution towards the bottom of the wells. The 96well reaction plate was then incubated on ice for 5 minutes before being transferred to an
Eppendorf thermocycler at 85 °C for 65 minutes.
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4. Real-time qPCR Amplification Recipe
Much like RT, a master mix was prepared and distributed on a reaction plate before
the samples were ready to be added and analyzed. The master mix recipe for qPCR for
the volume in each well is listed in Table VI below.
TABLE VI
MASTER MIXTURE RECIPE PER WELL FOR RT-QPCR
Component

Volume (𝝁L) per 10-𝝁L reaction

20X miRNA Primer

0.5

Universal Master Mix

5.00

Nuclease-free water

3.17

Total Volume

8.67

8.67 μL of master mix was prepared in individual wells of a 100 μL PCR 96-well
reaction plate for each sample analyzed. 1.33 μL of RT product was pipetted into its
respective well on the PCR 96-well reaction plate which was subsequently sealed and
gently mixed to ensure the solution was resting at the bottom of the well before running
real-time qPCR.

B. Experimental Procedure
1. CaRGOS Solution Stability With RNA.
DLS and zeta potential measurements were taken on 1.25 % v/v sol-gel solution
before and after being mixed to create the final CaRGOS solution. A 1.25 % v/v sol-gel
was prepared in the manner described in the sample preparation section and allowed to
settle for some time before initial measurements were taken. TE buffer and miRNA 21
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were then added and a second set of measurements was taken. This was done in order to
measure the size, dispersity, and stability of the silica sol-gel and track changes to the
network with the addition of buffer and RNA specimen.
2. TMOS Concentration Analysis.
This new sol-gel method for miRNA storage requires neither catalysts nor
cosolvents, which is favorable for further study on how the silica network and the
specimen interact. The effect of concentration and density of the silica in solution was
analyzed by introducing miRNA into 5 sol-gel solutions prepared with varying v/v %
TMOS precursor. A 20 % v/v TMOS mixture was hydrolyzed, and then through serial
dilution, solutions of 10 %, 5 %, 2.5 %, and 1.25 % were created and then combined with
TE buffer and NFW before spiking the solutions to ~500 nM miRNA 21. The recovery of
intact miRNA from the samples was quantified via RT, qPCR, and a calibration curve
available in APPENDIX I Figure 18.
3. Salinity Analysis.
Salt concentration is a key factor in both the sol-gel process and in the stabilization
of genetic materials. A more saline solution is preferable for sol-gel synthesis but
detrimental to the survival of RNA. Using a 1.25 % v/v TMOS sol-gel and the CaRGOS
formula described above, while varying the NaCl concentration between 0.15 M and 0.5
M, two sets of CaRGOS samples were prepared. The two sets of CaRGOS solution were
spiked to ~500 nM miRNA 21, and their stability was measured using RT and qPCR.
4. Time and Temperature Study.
Three sets of CaRGOS solution were prepared with 1.25 % v/v silica precursor and
0.15 M NaCl buffer. These samples, as well as a control sample without CaRGOS, were
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spiked to ~500 nM miRNA 21. One of the CaRGOS and the control sample were kept at
room temperature (25 °C), one CaRGOS was kept at elevated temperature (40 °C), and
the last CaRGOS was refrigerated (4 °C) for four weeks. An aliquot of each sample was
taken for quantification by qPCR at times of 1 day, 1 week, 2 weeks, 3 weeks, and 4
weeks after addition of miRNA.
5. Nuclease Inhibition Analysis.
Florescence emission measurements were used to study the shielding properties of
CaRGOS in the presence of aggressive proteases and nucleases. CaRGOS solution was
spiked with yeast RNA, bound to Ethidium bromide, to 1 mg/ml (0.077 M), and bovine
pancreatic RNase A was added at incremental concentrations from 0 to 1200 nM. This
experiment illustrated the CaRGOS technology’s capacity to defend against aggressors of
biological materials. The fluorescence of the mixture and a control buffer without
CaRGOS was monitored using a Zetasizer Nano ZS90.
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IV. RESULTS AND DISCUSSION OF RESULTS

A. CaRGOS Solution Stability With RNA
Ideally the network formation of sol-gel should occur within a short period of time
before the addition of the specimen. The silica nanoparticle formation was tracked with
DLS hydrodynamic size measurements with and without the addition of the TE buffer
and miRNA 21. Before the addition of the buffer and sample, a hydrodynamic radius of
~1 nm was observed in the sol-gel mixture, which changed to ~70 nm after their addition.
Full display of DLS, polydispersity index, and zeta potential measurements are displayed
in Table VII.
TABLE VII
DLS, PDI, & ZETA POTENTIAL MEASUREMENTS
Sample

DLS (nm)

PDI

CaRGOS w/out TE *0.79 ± 0.11
0.983 ± 0.026
Buffer (1.25 % v/v)
CaRGOS with TE
69.95 ± 0.47
0.308 ± 0.004
Buffer and miRNA
(0.5 % v/v)
* Hydrodynamic size <1 nm is insignificant

Zeta Potential (mV)
-22.07 ± 1.01
-20.04 ± 1.26

This observation falls in line with the reported trend [31] that silica sol-gel
nanoparticles aggregate more effectively at near neutral pH. Once introduced to the
buffer, the silica precursors have a stronger drive to form around and restrict the miRNA
backbone.
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B. Salinity and pH
Fluctuations in salt concentration as well as pH are well documented as being
detrimental to RNA but necessary for the formation of sol-gel nanoparticles over time. To
curb the effects of pH on miRNA 21, an as-bought TE buffer was utilized to maintain a
constant pH environment even in the presence of acidic silica precursor. Salt
concentration aids in the sol-gel aggregation process but could prove harmful to a sample
in too-high a concentration. Also, salinity has a ubiquitous effect on non-covalent
interactions between biospecimens and CaRGOS matrices. Previously, Buijs et.al. had
reported an electrostatic adsorption induced destabilization of proteins (e.g. RNase
A/Lysozyme) on 11 nm silica particles[54]. They had observed a superior electrostatic
attraction between proteins and silica nanosystems in low ionic strength buffer solutions,
compared to their high ionic strength counterpart environments. The high ionic strength
environment could significantly reduce the electrostatic attraction between the negatively
charged silica nanosystem and any positively charged RNase from environmental
contamination. Therefore, miRNA 21 storage and downstream processing in high salt
environment is highly susceptible to miRNA degradation via RNase contamination. After
preparing, processing, and analyzing CaRGOS solutions with 1.25 % v/v precursor and
NaCl concentrations of 0.5 M or 0.15 M, it was found that the lower saline TE buffer
returned comparable critical threshold (CT) values as the original 1.25 % v/v while
introducing more consistent stability to the system. The mean C T values can be seen in
Figure 8.
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FIGURE 8 – Mean CT Values of Low (0.15 M) and High (0.5 M) NaCl CaRGOS
In response to salt stress, the miRNA expression levels were C T = 31.1 ± 1.2 and
were CT = 11.5 ± 6.0 in high salt and low salt buffers respectively, which demonstrates
miRNA 21 instability in high saline environments. Therefore, the undetermined miRNA
21 levels in the high salt buffer environment were attributed to the (a) miRNA21
instability induced by RNase, present in the environmental contamination and (b) absence
of electrostatic adsorption induced destabilization of positively charged RNase on
negatively charged CaRGOS surface.
C. Effects of Silica Concentration
In order to determine the ideal recipe for CaRGOS, sol-gels were prepared with
different concentrations of TMOS precursor, and equal amounts of miRNA were added
to each set. Solutions with concentrations of 20 %, 10 %, 5 %, 2.5 %, and 1.25 % TMOS
were prepared, and each was spiked to miRNA 21 concentrations of ~500 nM. After
addition of analyte, aliquots were taken from each sample set and processed via RT using
a thermocycler and an RT precursor kit. Once completed, the samples were then analyzed
using qPCR amplification with an applied 0.1 C T threshold. All readings CT > 30 were
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considered to be NFW or minute contaminant contributions. Concentrations of miRNA
21 in CaRGOS were determined through mean CT values compared to standard
calibration curve Figure 19 in APENDIX I. Figure 9 shows the measured pH and miRNA
21 concentration of each CaRGOS formulation made with varying TMOS precursor
concentrations.

FIGURE 9 – Precursor Effects On pH & miRNA Recovery
The results of the TMOS precursor study were mixed. At higher concentrations it
was apparent that miRNA 21 preservation and recovery is neither easy nor viable. The
final CaRGOS product at higher concentrations is either a solid gel or a viscous fluid
from which sample recovery is difficult. The mechanism of stabilization of the miRNA is
a balanced combination of non-covalent interaction of the miRNA backbone with parts of
the silica sol-gel matrix, and favorable solution conditions with minimal interaction with
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the sample [28, 49, 55-57]. As the concentration of silica sol-gel increases, the balance is
shifted, and miRNA becomes less stable and recoverable from the solution. Increasing
the concentration of the sol-gel provides excessive restriction and immobilization of the
miRNA, to a point where separation and recovery is difficult and potentially harmful to
the sample[49]. At concentrations of 1.7 % v/v, 3.3 % v/v, and 6.6 % v/v the resulting
CaRGOS was too viscous and gel-like for single step recovery so separation by
centrifuge had to be employed. The stress of separating the miRNA backbone from a
dense silica network could easily break the molecule apart [58]. Additionally, the higher
concentration of sol-gel drops the pH of the CaRGOS to less habitable levels making
denaturization of the miRNA sample entirely possible while within the sol-gel matrix.
The lower two concentrations of silica sol-gel required no additional steps to recover
a quantifiable sample, all that was needed was a sterile pipette. This single step recovery
of high miRNA concentrations is preferable for a final, easy to use product. The small
amount of equipment and infrastructure required for sample storage, transport, and
recovery with CaRGOS is one of the qualities that sets it apart from most other methods
used [1, 2]. Between the two lower concentration formulations, 0.5 % v/v maintained its
low viscosity over long periods of time, where the 0.8 % v/v CaRGOS gradually became
more gel-like as time progressed due to the continued formation of silica sol-gel network
within the solution.
It was determined that experiments would proceed with the 0.5 % v/v TMOS
formulation because, though not quite as effective as some of the higher concentrations,
this formulation facilitated sample recovery due to its lower viscosity.
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D. Time and Temperature Study
To assess the validity of this new method, sample sets of ~500 nM miRNA with
CaRGOS were prepared and held at 4, 25, and 40 degrees Celsius, while another set of
500 nM miRNA 21 without CaRGOS was left at 25 degrees for comparison. At times of
1, 7, 14, 21, and 28 days, aliquots from each sample set were characterized using qPCR.
Figure 10 below shows the results of the miRNA recovery from all samples at each time
step.

FIGURE 10 – miRNA Recovery from CaRGOS at 4°, 25°, & 40°C
The control sample at room temperature was measured on initial day of storage after
brief incubation at room temperature. After less than one day at room temperature, the
control sample without CaRGOS loses roughly half initial miRNA concentration
illustrating the instability of miRNA. One full day of room temperature incubation
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sharply decreases the concentration within the control sample, and by the first week the
miRNA was entirely depleted. CaRGOS, on the other hand shows very favorable
preservation of the miRNA over the full 28 days at all temperatures.
Initial measurements of CaRGOS samples at the three temperatures appeared
slightly concerning, showing preservation of less than 100% of the starting miRNA 21
concentration after one full day of incubation with a high standard deviation. After 7
days, the values of miRNA appeared to increase from the first measurements. Subsequent
sets of measurements provided fluctuating mean C T values, increasing and decreasing
noticeably between weeks. Though odd, the trend of increasing and decreasing on
particular days is shared between all temperature sets. It is assumed that the fluctuation,
standard deviation, and overall increase in C T values is due to the gradual release of
methanol in the solutions over time [59]. This explains the standard deviation of the 1day measurements across all temperatures that is otherwise not present during subsequent
measurements. The methanol concentration would be highest during the first day and
would be significantly lower after 7, 14, 21, and 28 days. Additional increase in standard
deviation is observed at 28 days for 25° and 40°C. Regardless of fluctuations, measured
CT values and resulting calculated concentrations of miRNA 21 in CaRGOS solutions at
all temperatures provided preservation of ~100% initial sample concentration with easy
single step recovery at each time.
Comparison shows, irrefutably, that CaRGOS guarantees preservation of miRNA 21
at a wide range of temperatures with little to no signs of degradation, while the sample
without CaRGOS showed immediate degradation after one day and total denaturization
after one week.
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E. Shielding Capacity
Resulting fluorescence measurements from the incremental increase of RNase A
into CaRGOS are indicative of the shielding properties of the solution. Figure 11 plots
out the relative fluorescence of CaRGOS and control buffer solutions when introduced to
a range of RNase A concentrations between 0 and 320 nM.

FIGURE 11 – Fluorescence Measurements for 0 to 320 nM RNase A
When EtBr is intercalated with nucleic acids it increases in fluorescence dramatically
making it an ideal dye to enhance the fluorescence of RNA for analysis. When the
molecule EtBr is bound to is denatured in any way, the fluorescence decreases markedly,
which would facilitate the monitoring of RNA integrity under different conditions. In this
study, the relative fluorescence of EtBr bound to yeast RNA was monitored in samples
with and without 0.5% v/v CaRGOS that were exposed to increasing amounts of RNase
A, a compound with the specific purpose of attacking and denaturing RNA from foreign
sources such as viral exposure. The integrity of the RNA is correlated with the
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fluorescence observed with the addition of RNase A relative to the original fluorescence
of pristine RNA.
A trend is clearly illustrated in Figure 11 as the control samples undergo a relative
fluorescence quenching of roughly 40% while CaRGOS is, for the most part, unperturbed
as the RNase A concentration increases. Comparing relative fluorescence measurements
at each RNase concentration indicates that CaRGOS is providing total protection of the
RNA where it would otherwise suffer from attack by RNase.
The observed trend is attributed to RNase A inhibition by the CaRGOS solution via
electrostatic adsorption [24, 25, 60-62]. The general mechanism of RNA denaturization
via RNase attack is cleaving of the backbone at the Phosphorus in the backbone. RNase is
drawn to the RNA by electrostatic attraction between positively charged acid groups or
metal ligands on RNase to the negatively charged region of the RNA [54]. When bound
to silica sol-gel, however, RNase is deflected from attacking RNA and instead binds to
the net negative regions of silica and is destabilized. Figure 12 depicts an RNase
molecule attempting to attack strand of RNA nested inside a sol-gel network only to be
disarmed.

FIGURE 12 – CaRGOS RNase Inhibition and RNA Protection
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Though both RNA and the silica sol-gel are net negatively charged, the silica associates
with the backbone and non-covalently binds with it colinearly [27]. The presence of silica
on and around the RNA provides excellent steric support as well as a nearly impenetrable
chemical defense to the otherwise unstable and vulnerable biomolecule.
At RNase A concentrations higher than 320 nM however, the fluorescence increased
as shown Figure 20 in APPENDIX I. This increase in fluorescence is due to the sheer
amount of RNase A present, and EtBr binding with the silica network as well as the
remaining RNA [63, 64].

F. Immunotherapeutic Potential
Both components of the highly optimized aqueous formulations, CaRGOS (0.5 %
v/v) and miRNA 21, have potential as immunostimulants [19, 27, 48]. Previously, Cha
et.al. displayed the immunotherapeutic potential of mesoporous silica nanoparticles (2030 nm) against melanoma using a model tumor antigen [26]. Wang and Chen et.al had
also reported a significant immunoadjuvant effect with these irregularly porous silica
nanoparticles by encapsulating antigens and danger signal immunological molecules
(DAMP: damage associated molecular pattern) in their extra-large pores [6, 19]. Similar
to these tunable mesoporous silica nanoparticles, large-sized CaRGOS nanosystem (~ 69
nm) with its excellent buffer dispersions stability could be suitable as an
immunostimulant agent.
Furthermore, miRNA 21 molecules have been known to act as biomarkers in
cancer immunotherapy, regulating expressions of programmed death ligand (PD-L1) in
colorectal cancer [6, 8]. Consequently, miRNA 21 solutions in highly optimized aqueous
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formulations of the CaRGOS nanosystem could be potential immunostimulants in cancer
immunotherapy. With its thermal and chemical stability over long periods of time
availability and performance of drug availability and delivery.
The anthracycline doxorubicin (DOX) has strong synergistic interactions with
DNA/RNA and has a downregulating effect on immune checkpoint inhibitors (e.g. PDL1) [65, 66]. Zhu et. al. had demonstrated a multi-drug circumvention (MDR) strategy by
controlling the intracellular release of DOX using miRNA 16 mimics [53]. Also, Rubio
et.al. observed doxorubicin (DOX: Emission: 560-590 nm) fluorescence quenching after
DOX intercalation into RNA mimics [53, 65].

FIGURE 13 – Doxorubicin Quenching in CaRGOS with and without miRNA 21
As shown in the Figure 13, the DOX (50 μM) fluorescence quenching was
observed with CaRGOS [(0.5 – 7.0) % v/v; (pH: 6.0 - 7.5)] samples with and without
miRNA 21. This displays the combined effect of (a) DOX’s non-covalent interaction
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with miRNA 21 and (b) DOX’s intercalation into the CaRGOS silica matrices [53, 65].
DOX concentrations were similar at higher CaRGOS concentrations [(3.0 - 7.0) % v/v;
pH < 7] with and without miRNA 21, while a differential response of DOX fluorescence
quenching (9.6 – 17.0) μM was observed at lower CaRGOS concentrations [(0.5 – 1.7) %
v/v; pH > 7]. Such fluorescence quenching at lower CaRGOS concentration gradient is
attributed to the non-covalent DOX-miRNA interaction and a synchronized DOX –
CaRGOS intercalation, indicating the perseverance of the miRNA 21 integrity in such
CaRGOS aqueous formulations. On the other hand, the similar DOX concentration levels
in higher CaRGOS concentrations [(3.0 - 7.0) % v/v; pH < 7] indicates loss of miRNA 21
stability in their aqueous media. The DOX concentrations (μM) of CaRGOS samples
were evaluated by measuring mean fluorescence values (FL) using standard calibration
curves at modulus fluorimeter (Green module: Emission: 580 - 640 nm), APPENDIX I
Figure 21. Therefore, the aliquots of CaRGOS (0.5 wt./v %) based aqueous formulations
with their DOX/miRNA 21 suspension could potentially demonstrate adjuvant effect in
cancer immunotherapy or macromolecular (CaRGOS/miRNA) conjugation induced
multidrug resistance effect respectively [19, 26, 53, 63, 67].
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V. CONCLUSIONS

CaRGOS has proven to be a novel, quick, and easy formulation which facilitates
long-term storage and preservation of miRNA 21 at refrigeration, room, and elevated
temperatures while allowing quick, easy, and complete recovery. The environment
created within CaRGOS allows for non-covalent interaction within the silica
nanoparticles that restricts the movement of the miRNA backbone, while at the same time
inhibiting harmful RNase and contaminant interaction with the sample. Fine-tuned pH,
low ionic strength, and their large hydrodynamic size are attributes that lend themselves
to the denaturing of contaminants harmful to miRNA. Recovery of miRNA over several
weeks at room and elevated temperatures shows that the natural inclination for unstable
biomolecules to denature themselves is being suppressed within the silica network. This
method shows unique and well-rounded protective measures. Being long lasting under a
variety of otherwise unfavorable temperatures, while so easy to prepare, makes CaRGOS
an invaluable tool for research of biomolecules.
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HEMOGLOBIN CARGOS
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OVERVIEW

Metalloproteins, in general, are greatly associated with human health. Hemoglobin
binds and transport analytes (i.e., oxygen, nitric oxide, carbon monoxide) and plays
significant role in the regulation of blood pressure. Hemoglobin is a model protein chosen
for investigating the preservation of structural integrity under environmental stimuli
(heat, mechanical excursions, nuclease/protease/microbial contamination), due to its
complex four protein-chain framework, with each chain having heme group and metal
center (i.e., iron) in the central cavity. Purified proteins in their native state are known to
be slightly disordered and for having certain sections in their unfolded state [68].
Therefore, instead of investigating secondary structures (i.e., α-helix), thermal stability (~
25 °C) and mechanical handling (mixing, vortexing, shaking) investigations with
CaRGOS-hemoglobin formulations are focused on the analysis of heme groups of the
four-polypeptide chain network of hemoglobin. Previously, Chen et.al. had developed a
silica-gel (powder) based room-temperature storage of proteins (i.e., Lysozyme) [27].
However, post-ensilication, the protein - reconstitution in aqueous buffers at roomtemperature is partly analogous to a conventional reconstitution of freeze-thawed or
lyophilized proteins and therefore could denature the protein nativity. In this paper, the
room-temperature stability and mechanical handling of hemoglobin in aqueous CaRGOS
formulations will be addressed, developing an ambient-temperature based alternative
strategy to preserve metalloprotein’s nativity, homogeneity, activity and reproducibility
over long-term storage.
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II. INSTRUMENTATION AND EQUIPMENT

A. Infrastructure and Equipment
Sterile laminar hood
Fume hood
Microwave 1200 Watt with viewing window in order to monitor samples during use.
Vortex machine
DLS machine
UV-Vis spectrophotometer
Centrifuge
Micropipettes capable of measuring as little as 0.5 uL
Sealable glass vessel with 2-3 ventilation holes in the cap for gasified methanol

B. Chemicals
Tetramethyl orthosilicate 99% (TMOS) from Acros Organics.
Nuclease free water (NFW)
Sodium Phosphate dibasic from Sigma Aldrich.
Sodium Phosphate monobasic from Sigma Aldrich.
Potassium Hydroxide from Sigma Aldrich
Polyethylene Glycol from Sigma Aldrich.
Sulfuric Acid from VWR
Polymethylmethacrylate UV-grade cuvettes from VWR.
Freeze dried Hemoglobin from VWR.
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III. PROCEDURE

A. Sample Preparation
1. Hemoglobin Stock Solution
A 1%wt stock solution of hemoglobin is used to create all following samples for
analysis. Freeze-dried hemoglobin is weighed out into sterile, sealable containers and
previously prepared 0.5M NaPb is used to rehydrate hemoglobin. In order to preserve
hemoglobin until the time of testing all samples are kept in the refrigerator prior to all
experimentation.
2. Phosphate Buffer
In order to provide additional stability to hemoglobin, a 0.5M sodium phosphate
buffer (NaPb) of pH 8.20 was chosen. Using a modified Henderson-Hasselbalch
Equation, Equation XX, the appropriate amounts of sodium phosphate monobasic, and
conjugate base sodium phosphate dibasic were derived.

(Equation XX)

[

𝑝𝐻 = 𝑝𝐾 + 𝑙𝑜𝑔 [

[𝑁𝑎𝑃 ]
= 10(
[𝑁𝑎𝑃 ]

[𝑁𝑎𝑃 ] = [𝑁𝑎𝑃
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]
]

)

] − [𝑁𝑎𝑃 ]

[𝑁𝑎𝑃

] − [𝑁𝑎𝑃 ] [𝑁𝑎𝑃
]
=
− 1 = 10(
[𝑁𝑎𝑃 ]
[𝑁𝑎𝑃 ]
[𝑁𝑎𝑃 ] =

[𝑁𝑎𝑃
1 − 10(

)

]
)

= [𝑁𝑎𝑃 ] × 𝑉 × 𝑀𝑊

𝑀

Minor adjustments to achieve a final pH of 8.20 were made by titrating with potassium
hydroxide and 0.5M sulfuric acid.
3. CaRGOS Solution
With hemoglobin and NaPb solutions available, a 10% v/v sol-gel stock solution is
prepared. Once all components are available, 1%wt hemoglobin is suspended in 0%,
0.5%, 1%v/v sol-gels with 0.45M NaPb, 2.5%v/v sol-gels with 0.445M NaPb, 5%v/v solgels with 0.25M NaPb, and 7.5% sol-gels with 0.125M NaPb by combining the necessary
quantities listed in Table VIII.
TABLE VIII
RECIPE FOR HEMOGLOBIN CARGOS SAMPLES OF (0 – 7.5 V/V%) GEL

Component

Volume (mL) per cuvette
0%v/v

0.5%v/v

1%v/v

2.5%v/v

1%wt
Hemoglobin

0.03

0.03

0.03

0.03

0.5M NaPb

2.67

2.67

2.67

2.22

1.47

0.72

10%v/v Sol-Gel

0

0.15

0.30

0.75

1.50

2.25

NFW

0.30

0.15

0.00

0.00

0.00

0.00

Total Volume

3.00

3.00

3.00

3.00

3.00

3.00
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5%v/v
0.03

7.5%v/v
0.03

B. Experimental Procedure
1. Time and Temperature Study.
To assess integrity of hemoglobin within the samples over time, UV-vis
spectroscopy was run on 2 cuvettes of each sample immediately after preparation, and 3,
6, 10, 13, 17, 20, 24, 27 and 31 days since initially stored at room temperature.
Quantification of hemoglobin preservation was assessed by relative peak intensity of the
406 nm band, characteristic of the prosthetic heme group (C 34H32O4N4Fe).
2. CaRGOS Size and Stability With Hemoglobin
The zeta potential and hydrodynamic size was measured for both CaRGOS (0.0, 0.5,
& 1.0 % v/v TMOS; 0.5 M NaPb, pH 8.2; 3.0 mL) and CaRGOS-hemoglobin (0.0, 0.5, &
1.0 % v/v TMOS; 0.01 wt./v % Hemoglobin; 0.5 M NaPb, pH 8.2; 3.0 mL) dispersions
using a NanoBrook Zeta PALS Zeta Potential Analyzer. The voltage of 3.0 V and
frequency of 20.0 Hz was optimized to analyze stability of CaRGOS in high salt
environment. The zeta potential and size were reported as an average and standard
deviation of 10 readings per sample
3. Recovery of Hemoglobin
The UV-Vis spectra of stored CaRGOS-hemoglobin (0.0 - 7.5 % v/v TMOS; 0.01
wt./v % Hemoglobin; 0.5 M NaPb, pH 8.2; 3.0 mL) solutions were recorded on 0, 1,14,
24 and 31days to validate integrity of hemoglobin in the CaRGOS formulations.
Polyethylene glycol (65.0 M, 1.0 mL) was transferred to CaRGOS-hemoglobin samples
(1.0- 7.5 % v/v TMOS; 0.01 wt./v % Hemoglobin; 0.5 M NaPb, pH 8.2; 3.0 mL) for
facile re-dissolution of the silica-dispersions and another set of UV-Vis spectra were
recorded.
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IV. Results and Discussion of Results

A. Room Temperature Preservation
UV-Vis spectroscopy is a rapid method to validate reproducibility and stability of
hemoglobin in the various CaRGOS formulations (0.0 – 7.5 % v/v) at room-temperature
via 406 nm band representative of the heme group as well as to detect the presence of
nuclease via 260 nm bump, shoulder or band arising from environmental contamination
in the CaRGOS formulations. As shown in the Figure 14, a sharp 406 nm UV-Vis band
characteristic of the prosthetic heme group was observed with hemoglobin solutions and
decreases as denaturation of the native structure occurs.

FIGURE 14 – UV-Vis Spectrum of Hemoglobin Degrading in Room Temperature
Storage Over Time
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While keeping hemoglobin concentration and buffer environment fixed, the
CaRGOS concentration was varied to observe the long-term (~31 days) roomtemperature stability of hemoglobin. An unaltered 406 nm UV-Vis absorbance band was
observed over 31 days in high gel concentration CaRGOS (5.0 & 7.5 % v/v) solutions,
inferring a thermally stable hemoglobin. However, a significant decrease in UV-Vis
absorbance of heme group was observed with rest of the CaRGOS formulations (0.0 -2.5
% v/v), demonstrating a CaRGOS-concentration dependent trend in determining the
physical and chemical stability of hemoglobin dispersions.
A control group of hemoglobin solutions without CaRGOS stored at roomtemperature had demonstrated a significant decrease in UV-Vis absorbances: ~ 10 % in
1-week, ~ 20 % in 3- weeks and ~ 63 % in four weeks respectively. Notably, the
complete denaturation of hemoglobin was not observed over 4-weeks. This inherently
robust-stability of hemoglobin solutions is also facilitated by the non-contaminated buffer
solutions and a careful downstream analysis. In contrast to ~ 63 % denaturation of
hemoglobin control over 4 weeks, a differential response was observed in presence of
CaRGOS formulations. Hemoglobin stability increases with each increment in CaRGOS
concentration within the experimental range.
Relative to the control-group hemoglobin solutions, a two-fold and three-fold
increase in hemoglobin stability was observed within 1.0 % v/v and 2.5 % v/v CaRGOS
respectively as seen in Figure 15.
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FIGURE 15 – Measured Change in Hemoglobin Peak Intensity in CaRGOS
Notably, all CaRGOS formulations had demonstrated significant hemoglobin
stability up to 3-weeks storage at ambient temperature, with a small 0.0 -12.0 %
degradation in the total hemoglobin content of the stored CaRGOS formulations.
However, the high gel CaRGOS (5.0 and 7.5 % v/v) solutions had demonstrated nearly
100 % hemoglobin-stability up to 3-weeks and 94 % stability in 31 days under roomtemperature and mechanical-handling (i.e., mixing, vortexing) based storage conditions.
An incremental stability of hemoglobin dispersions in CaRGOS formulations is
attributed to the inherently dual-capabilities of silica formulations. As previously
mentioned, silica formulations have been known to stabilize biospecimens by (a)
immobilizing their native conformation in their matrices and by (b) circumventing
nucleolytic and proteolytic hydrolysis of biomacromolecule’s backbone, via non-covalent
interaction (i.e., electrostatic, van der waals) that induce unfolding of nuclease or
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protease. The 1.0 % v/v CaRGOS formulations are highly aqueous and contains an
insignificant amount of silica content to immobilize the hemoglobin. Nevertheless, a twofold increment in hemoglobin stability was still observed in this formula against the
control hemoglobin solutions. This unique stabilization of hemoglobin is attributed to the
nuclease or protease inhibiting capabilities of these silica formulations. The large-sized
nanostructures (nm) with limited curvature, large surface of contact and high surface
potential silica nanostructures (i.e., solid core, mesoporous) in low-salt buffer solutions
had been known to unfold nuclease and avert protease activity.
B. CaRGOS Size and Stability with Hemoglobin
The hydrodynamic size (nm) and Zeta potential (mV) measurements were
performed on the stored CaRGOS solutions, with and w/o hemoglobin on 0, 7 and 14
days, shown in Table IX.
TABLE IX
SIZE AND STABILITY OF HEMOGLOBIN CARGOS SUSPENSIONS OVER TIME
CaRGOS
Concentration(v/v)
%
0
0 (with
Hemoglobin)
0.5
0.5 (with
Hemoglobin)
1.0
1.0 (with
Hemoglobin)

DLS (nm)

PDI

Day
0

Day 7

Day
14

Day
0

Day
7

Day
14

1388 
624.8
817.9
 85.75

233.10 
203.60
1616.00 
804.20

-

0.501 
0.281
1.000 
0.000

-

668.7 
194.1

1.000 
0.000
0.764 
0.060

933.0 
29.39
830.0 
53.83

648.20 
56.12
714.5 
495.9

437.6 
125.3
297.8 
45.70

1.000 
0.000
0.984 
0.027

232.2 
45.38
423.8 
120.8

4302 
2590
1317 
313.2

313.4 
119.6
364.6 
133.8

0.983 
0.030
1.000 
0.000
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Zeta
Potential
(mV)
Day
Day
7
14

0.919 
0.095

7.52 
13.35
-1.77 
3.79

-2.66 
1.11
6.39 
15.17

1.000 
0.000
0.910 
0.155

0.949 
0.047
1.000 
0.000

-6.30 
1.35
-7.57 
3.50

-18.75
 7.84
-19.55
 7.49

0.753 
0.427
0.351 
0.180

0.909 
0.158
0.971 
0.050

-6.06 
1.60
14.45 
18.66

-19.63
 9.99
-9.30 
0.92

The colloidal dispersions of 0.0, 0.5, and 1.0 % v/v CaRGOS with and without
hemoglobin had displayed the hydrodynamic sizes in 200- 2000 nm range and a PDI ~
1.0, indicating highly-polydisperse and large hydrodynamic-sized nanostructures. The
similar hydrodynamic sizes of CaRGOS formulations, with and without hemoglobin is
tentatively attributed to a unique shape-recognition feature of silica nanostructures. These
porous silica nanostructures may deposit congruently to the hemoglobin native
conformation and match the protein shape and size, resulting in similar hydrodynamic
sizes and PDI values.
A zeta potential in a – 25.0 mV to + 25.0 mV range was observed for CaRGOS
formulations with and w/o hemoglobin, indicating instability of CaRGOS matrices in
phosphate buffer dispersions. However, zeta potential of -(6.0 – 25.0) mV was observed
with 0.5 % v/v CaRGOS formulations, with and without hemoglobin, which displayed
fair stability and resistance to aggregation in NaPb dispersions. The superior stability of
0.5 % v/v CaRGOS formulations over the rest of the CaRGOS formulations is due to
finely dispersing CaRGOS nanostructures in comparison to highly viscous and
sedimenting silica matrices in NaPb dispersions, respectively.
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C. Hemoglobin Recovery.
A quick re-dissolution of more viscous CaRGOS-hemoglobin formulations was
observed upon addition of polyethylene glycol or PEG (65μM, 2KDa). Figure 16 shows a
three to five-fold increase in hemoglobin’s UV-Vis absorbance (406 nm) in the CaRGOS
formulations upon PEGylation.

FIGURE 16 – Percent Yield of Recoverable Hemoglobin from CaRGOS Matrix
This large increment in the absorbance intensity of heme group is attributed to a
synergistic hydrophilicity imparted by PEG to the CaRGOS silica formation, allowing a
facile passage and release of hemoglobin from the CaRGOS matrices without any loss of
protein nativity. As previously mentioned, an ideal ensilication matrix allows efficient
bioanalyte immobilization (i.e., encapsulation entrapment or collaterally depositing) and
a facile passage without any physical rupture. Therefore, the highly porous and
moderately viscous CaRGOS formulations require PEGylation for protein-retrieval after
long-term storage.
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V. CONCLUSIONS

CaRGOS was synthesized by a standard microwave method and hemoglobin protein
was stored in it under slightly basic buffer conditions. UV-Vis, DLS, and zeta potential
measurements were performed to analyze hemoglobin’s thermal and mechanical (i.e.,
mixing, vortexing) stability over 31 days. Silica nanomatrices stabilizes biospecimens by
immobilization of biospecimens and inhibition of environmental contamination (i.e.,
nuclease and protease). This is particularly evident based on the UV-Vis analysis of high
concentration CaRGOS (5.0 & 7.5) v/v % formulations, which displayed excellent
stability of hemoglobin protein over 31 days. At low concentration CaRGOS (1.0 v/v%)
formulations with tiny silica content, the hemoglobin solutions are fairly stable based on
UV-Vis analysis, deciphering a strong correlation between hemoglobin stability and
nuclease or protease averting capability of silica matrices. DLS studies confirmed a
highly polydisperse nanostructure framework of CaRGOS formulations and zeta potential
studies shows that only intermediate CaRGOS (0.5 v/v %) concentrations are stable in
phosphate buffer dispersions. The robust storage and transport are the promise of this
innovation. Thermal stability studies with other proteins are currently underway.
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VI. RECOMMENDATIONS

Though the application of CaRGOS has been proven viable with miRNA storage
and preservation, there are still more ways sol-gel solutions can be tuned to assist in
biomolecular and pharmaceutical endeavors. With the simplicity of the CaRGOS
manufacturing process it could easily be incorporated into a microfluidics system. Lab on
a chip research could also be improved by incorporating CaRGOS as a stabilizing agent
for proteins and other unstable macromolecules.
Molecular dynamics simulations would also be a direction that future studies of
CaRGOS could branch into. With computational chemistry and known properties of
many biomolecules already available, ideal solution conditions for CaRGOS applications
for many other biomolecules could be derived mathematically and then tested
experimentally rather than the other way around.
With CaRGOS formulation proving to have potential application in cancer
immunotherapy and MDR studies by conjugating doxorubicin to CaRGOS and RNA
architectures, studies should be conducted with living subjects to test its feasibility in
practice.
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APPENDIX I

y = (x + 4.5488) / 253.46
R² = 0.9998

FIGURE 17 – Raman Peak Intensity Vs. Methanol Volume Percent Calibration Curve
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FIGURE 18 – Critical Threshold Vs. miRNA 21 Concentration: 0.5 % v/v CaRGOS
Solution Calibration Curve

FIGURE 19 – Critical Threshold Vs. miRNA 21 Concentration Calibration Curve for
Salinity Study
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FIGURE 20 – Relative Fluorescence Intensity of Ethidium Bromide Vs. RNase A
Concentration Range 0-1200nM

FIGURE 21 – Fluorescence Vs. DOX Concentration Calibration Curve
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